As the October onset of the CMS' decision not to pay for some "never events" approaches, hospitals are faced with a daunting array of products meant to combat healthcare-associated infections. One option is rapid testing for MRSA, which Keith Ramsey, left, says cost his hospital $950,000 in the first year, but it recouped $700,000 from payer reimbursement for testing. He says it was a smart investment.